Butorphanol in Pain Following Ablation for Hepatic Tumor

Bibo Wang

Status: Completed

Conditions: Visceral Pain; Microwave Ablation; Hepatic Tumor

Treatments: Drug: normal saline; Drug: Butorphanol

Study type: Interventional

Funder types: Other

Identifiers

NCT06031129

Jinling WBB

Details and patient eligibility

About

The objective of this investigation was to evaluate the influence of Butorphanol on postoperative pain mitigation in patients undergoing microwave ablation for hepatic tumor. Employing a rigorously designed multicentral, randomized, and placebo-controlled format, patients subjected to microwave ablation were assigned randomly to either Butorphanol (experimental group) or normal saline (control group). Primary outcomes encompassed intraoperative pain levels assessed through patient-driven evaluation utilizing a 10-point visual analog scale (VAS). Secondary outcomes included postoperative pain levels at the 6-hour mark (VAS) and comprehensive pain assessment outcomes.

Enrollment: 300 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

patients performing Microwave Ablation sign the informed consent

Exclusion criteria

Patients with a body mass index > 30 kg/m2 a history of depression opioid dependence poorly controlled hypertension (systolic blood pressure > 180 mmHg) myocardial infarction severe liver disease significant abdominal pain before surgery patients with sensory system or language dysfunctions who could not cooperate to complete the scale pregnant women.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

300 participants in 2 patient groups, including a placebo group

Butorphanol

Experimental group

Treatment:

Drug: Butorphanol

normal saline

Placebo Comparator group

Treatment:

Drug: normal saline